美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

NewcelX Ltd.

3.30

-0.0755-2.23%

盤後：3.300.00000.00%19:30 EDT

成交量：3,750

成交額：1.23萬

市值：1,766.32萬

市盈率：-1.53

高：3.32

開：3.30

低：3.22

收：3.38

52周最高：24.60

52周最低：1.83

股本：534.52萬

流通股本：273.89萬

量比：0.79

換手率：0.14%

股息：- -

股息率：- -

每股收益(TTM):-2.1600

每股收益(LYR):-2.1592

淨資產收益率：--

總資產收益率：-25.94%

市淨率：2.44

市盈率(LYR):-1.53

資料載入中...

總覽公司新聞公告

NewcelX任命世界知名糖尿病治療先驅Camillo Ricordi博士加入科學顧問委員會

Newcelx宣佈FDA臨床前會議成功，為Ncel-101啓動1型糖尿病臨床試驗鋪平道路

NewcelX公布2025財年業績攜手Eledon製藥加速推進2026年1型糖尿病療法研發進程

Newcelx更新企業演示文稿，重點展示與Eledon製藥戰略合作後的1型糖尿病旗艦項目，瑞士生物技術會議前揭曉

BUZZ--美國股票走勢-Cal-Maine, Rivian, Alkermes

BUZZ-NewcelX 溢價融資以推動糖尿病項目，隨後股價上漲

Newcelx攜手Eledon製藥推進Ncel-101項目開啓1型糖尿病治療新篇章

Newcelx Ltd.盤中異動早盤急速拉升5.48%

Newcelx Ltd.盤中異動臨近收盤股價大漲5.11%報2.78美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/NCEL/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NCEL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","market":"US","secType":"STK","nameCN":"NewcelX Ltd.","latestPrice":3.3045,"timestamp":1789156800000,"preClose":3.38,"halted":0,"volume":3750,"hourTrading":{"tag":"盘后","latestPrice":3.3045,"preClose":3.3045,"latestTime":"19:30 EDT","volume":5,"amount":16.5,"timestamp":1789169404893,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.022337278106508845,"floatShares":2738900,"shares":5345200,"eps":-2.159999,"marketStatus":"休市中","change":-0.0755,"latestTime":"09-11 16:00:00 EDT","open":3.3,"high":3.323748,"low":3.2239,"amount":12342.291,"amplitude":0.029541,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.159999,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1611896400000,"exchange":"NASDAQ","adjPreClose":3.38,"postHourTrading":{"tag":"盘后","latestPrice":3.3045,"preClose":3.3045,"latestTime":"19:30 EDT","volume":5,"amount":16.5,"timestamp":1789169404893,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7859328482501303},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","floatShares":2738900,"roa":"-25.94%","roe":"--","lyrEps":-2.159218,"volumeRatio":0.7859328482501303,"shares":5345200,"dividePrice":0,"high":3.323748,"amplitude":0.029541,"preClose":3.38,"low":3.2239,"week52Low":1.8299,"pbRate":"2.44","week52High":24.6,"institutionHeld":0,"latestPrice":3.3045,"eps":-2.159999,"divideRate":0,"volume":3750,"delay":0,"ttmEps":-2.159999,"open":3.3,"prevYearClose":1.9,"prevWeekClose":3.35,"prevMonthClose":3.275,"prevQuarterClose":3.66,"fiveDayClose":3.35,"twentyDayClose":3.6,"sixtyDayClose":3.21},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCEL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-04-30","symbol":"NCEL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1777521600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2025-10-31","symbol":"NCEL","defaultRemindTime":1761917400000,"type":"split","dateTimestamp":1761883200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-05-16","symbol":"NCEL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1747368000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-09-27","symbol":"NCEL","defaultRemindTime":1727443800000,"type":"split","dateTimestamp":1727409600000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCEL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCEL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1784001600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCEL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCEL","date":"2026-09-11","current":-1.529862,"percent":0.098592,"low":-2.743828,"twenty":-2.24955,"median":-0.871696,"eighty":-0.593951,"high":-0.434312,"avg":-1.335035,"sd":0.793932,"marketCap":19523312},"quantilePoints":[{"date":"2025-10-31","current":-2.085416,"twenty":-2.085416,"median":-2.085416,"eighty":-2.085416,"marketCap":39937082.48},{"date":"2025-11-07","current":-0.993097,"twenty":-1.495376,"median":-1.229626,"eighty":-1.098389,"marketCap":18917268},{"date":"2025-11-14","current":-0.808829,"twenty":-1.253274,"median":-0.970727,"eighty":-0.876223,"marketCap":15635236},{"date":"2025-11-21","current":-0.750891,"twenty":-1.145695,"median":-0.878334,"eighty":-0.814355,"marketCap":14358890},{"date":"2025-11-28","current":-0.957951,"twenty":-1.045743,"median":-0.867781,"eighty":-0.806793,"marketCap":18279095},{"date":"2025-12-05","current":-0.856292,"twenty":-0.972009,"median":-0.871696,"eighty":-0.812974,"marketCap":16455744},{"date":"2025-12-12","current":-0.781666,"twenty":-0.995845,"median":-0.875612,"eighty":-0.812974,"marketCap":15179398},{"date":"2025-12-19","current":-0.635834,"twenty":-0.972009,"median":-0.85736,"eighty":-0.781019,"marketCap":12353204},{"date":"2025-12-26","current":-0.613233,"twenty":-0.957493,"median":-0.83848,"eighty":-0.693066,"marketCap":11988534},{"date":"2026-01-02","current":-0.442896,"twenty":-0.955117,"median":-0.833152,"eighty":-0.615876,"marketCap":8660918},{"date":"2026-01-09","current":-0.513637,"twenty":-0.941907,"median":-0.808829,"eighty":-0.589968,"marketCap":10074015},{"date":"2026-01-16","current":-0.561129,"twenty":-0.915578,"median":-0.78535,"eighty":-0.566624,"marketCap":11122442},{"date":"2026-01-23","current":-0.610165,"twenty":-0.913462,"median":-0.76547,"eighty":-0.561129,"marketCap":12125285},{"date":"2026-01-30","current":-0.576613,"twenty":-0.882218,"median":-0.6841,"eighty":-0.565731,"marketCap":11623863},{"date":"2026-02-06","current":-0.601541,"twenty":-0.878334,"median":-0.628521,"eighty":-0.570197,"marketCap":12034117},{"date":"2026-02-13","current":-0.627168,"twenty":-0.875612,"median":-0.627168,"eighty":-0.572325,"marketCap":12717874},{"date":"2026-02-20","current":-0.632256,"twenty":-0.869347,"median":-0.627168,"eighty":-0.573006,"marketCap":12581123},{"date":"2026-02-27","current":-0.656951,"twenty":-0.860299,"median":-0.626808,"eighty":-0.575926,"marketCap":13082544},{"date":"2026-03-06","current":-0.638142,"twenty":-0.856719,"median":-0.630594,"eighty":-0.581513,"marketCap":12854625},{"date":"2026-03-13","current":-0.639458,"twenty":-0.843011,"median":-0.628376,"eighty":-0.587749,"marketCap":12717874},{"date":"2026-03-20","current":-0.559522,"twenty":-0.837754,"median":-0.626853,"eighty":-0.587749,"marketCap":11168026},{"date":"2026-03-27","current":-0.565498,"twenty":-0.835865,"median":-0.623182,"eighty":-0.571899,"marketCap":11259193},{"date":"2026-04-02","current":-0.537802,"twenty":-0.83268,"median":-0.620613,"eighty":-0.56375,"marketCap":10712188},{"date":"2026-04-10","current":-0.468376,"twenty":-0.821759,"median":-0.618412,"eighty":-0.555851,"marketCap":9527010},{"date":"2026-04-17","current":-0.546102,"twenty":-0.811592,"median":-0.616697,"eighty":-0.55169,"marketCap":11350361},{"date":"2026-04-24","current":-1.072253,"twenty":-0.811592,"median":-0.617492,"eighty":-0.552903,"marketCap":22381635},{"date":"2026-05-01","current":-0.95322,"twenty":-0.83268,"median":-0.620255,"eighty":-0.55452,"marketCap":20102446},{"date":"2026-05-08","current":-1.779415,"twenty":-0.838489,"median":-0.62112,"eighty":-0.555851,"marketCap":14769144},{"date":"2026-05-15","current":-2.224901,"twenty":-0.870913,"median":-0.625846,"eighty":-0.556353,"marketCap":18466677},{"date":"2026-05-22","current":-2.062736,"twenty":-0.91452,"median":-0.627168,"eighty":-0.558257,"marketCap":17120709},{"date":"2026-05-29","current":-2.296253,"twenty":-0.955372,"median":-0.628812,"eighty":-0.55988,"marketCap":19058903},{"date":"2026-06-05","current":-2.043276,"twenty":-1.009476,"median":-0.634045,"eighty":-0.560702,"marketCap":16959193},{"date":"2026-06-12","current":-2.118586,"twenty":-1.18766,"median":-0.639458,"eighty":-0.562877,"marketCap":17584261},{"date":"2026-06-18","current":-2.043276,"twenty":-1.814564,"median":-0.642142,"eighty":-0.565545,"marketCap":16959193},{"date":"2026-06-26","current":-2.30274,"twenty":-1.957423,"median":-0.652667,"eighty":-0.566624,"marketCap":19112742},{"date":"2026-07-02","current":-2.497338,"twenty":-2.043276,"median":-0.658096,"eighty":-0.570197,"marketCap":20727903},{"date":"2026-07-10","current":-2.678962,"twenty":-2.05625,"median":-0.697542,"eighty":-0.572325,"marketCap":22235387},{"date":"2026-07-17","current":-2.536257,"twenty":-2.075709,"median":-0.73457,"eighty":-0.573176,"marketCap":21050935},{"date":"2026-07-24","current":-2.464905,"twenty":-2.085416,"median":-0.750891,"eighty":-0.576613,"marketCap":20458709},{"date":"2026-07-31","current":-2.180403,"twenty":-2.102953,"median":-0.781666,"eighty":-0.580006,"marketCap":18097343},{"date":"2026-08-07","current":-2.166522,"twenty":-2.154845,"median":-0.801508,"eighty":-0.582361,"marketCap":17982129},{"date":"2026-08-14","current":-2.335173,"twenty":-2.160035,"median":-0.815737,"eighty":-0.587749,"marketCap":19381935},{"date":"2026-08-21","current":-2.185981,"twenty":-2.167171,"median":-0.833563,"eighty":-0.589629,"marketCap":18143645},{"date":"2026-08-28","current":-2.380043,"twenty":-2.188576,"median":-0.837687,"eighty":-0.590513,"marketCap":19754357},{"date":"2026-09-04","current":-2.331329,"twenty":-2.227496,"median":-0.85736,"eighty":-0.590877,"marketCap":19350028},{"date":"2026-09-11","current":-2.352206,"twenty":-2.24955,"median":-0.871696,"eighty":-0.593951,"marketCap":19523312}],"updateTime":1789330524687},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCEL\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1188974254","title":"NewcelX任命世界知名糖尿病治療先驅Camillo Ricordi博士加入科學顧問委員會","url":"https://stock-news.laohu8.com/highlight/detail?id=1188974254","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188974254?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 21:22","pubTimestamp":1783516979,"startTime":"0","endTime":"0","summary":"NewcelX Ltd.宣布，已正式聘请国际知名糖尿病治疗领域先驱Camillo Ricordi博士加入其科学顾问委员会。这一重要人事任命标志着公司在糖尿病创新疗法研发方面迈出了关键一步。\nRicordi博士在胰岛移植和免疫耐受研究领域享有崇高声誉，其开创性工作为糖尿病治疗带来了革命性前景。他的加入预计将为NewcelX的科学战略方向提供权威指导，并加速相关治疗方案的临床转化进程。\n公司表示，此次引进顶尖学术人才，旨在强化研发管线的科学基础，并进一步提升在细胞治疗领域的核心竞争力。业界观察人士认为，该举措可能对NewcelX未来在代谢疾病治疗市场的布局产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121312334","title":"Newcelx宣佈FDA臨床前會議成功，為Ncel-101啓動1型糖尿病臨床試驗鋪平道路","url":"https://stock-news.laohu8.com/highlight/detail?id=1121312334","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121312334?lang=zh_tw&edition=fundamental","pubTime":"2026-07-01 21:35","pubTimestamp":1782912913,"startTime":"0","endTime":"0","summary":"Newcelx宣布，其与FDA就Ncel-101项目举行的临床前会议取得圆满成功，为推进该疗法针对1型糖尿病的临床试验明确了清晰的路径。此次会议成果标志着公司在该创新疗法的开发进程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191094520","title":"NewcelX公布2025財年業績 攜手Eledon製藥加速推進2026年1型糖尿病療法研發進程","url":"https://stock-news.laohu8.com/highlight/detail?id=1191094520","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191094520?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 20:17","pubTimestamp":1777551441,"startTime":"0","endTime":"0","summary":"生物技术公司NewcelX Ltd. 近日正式披露2025年度财务报告，同时向投资者同步了与Eledon Pharmaceuticals, Inc. 合作研发1型糖尿病治疗方案的重大进展。据悉，双方将于2026年全面加速该创新疗法的临床开发进程，标志着代谢疾病治疗领域或将迎来突破性技术迭代。若临床进展符合预期，该联合疗法或将成为全球首款通过免疫调控机制逆转1型糖尿病病理进程的生物制剂，潜在市场空间可观。随着研发进程的加速，NewcelX与Eledon制药的技术协同效应将持续释放价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174997049","title":"Newcelx更新企業演示文稿，重點展示與Eledon製藥戰略合作後的1型糖尿病旗艦項目，瑞士生物技術會議前揭曉","url":"https://stock-news.laohu8.com/highlight/detail?id=1174997049","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174997049?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 19:37","pubTimestamp":1776685035,"startTime":"0","endTime":"0","summary":"Newcelx已更新其企业演示文稿，着重强调与Eledon制药达成战略合作后的1型糖尿病旗舰项目。这一更新恰逢瑞士生物技术会议召开前夕，凸显了公司对该项目的重视与推进决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624519529","title":"BUZZ--美國股票走勢-Cal-Maine, Rivian, Alkermes","url":"https://stock-news.laohu8.com/highlight/detail?id=2624519529","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624519529?lang=zh_tw&edition=fundamental","pubTime":"2026-04-01 21:14","pubTimestamp":1775049296,"startTime":"0","endTime":"0","summary":".N** Blackstone Inc BX.N:BUZZ - 赌博公司 Cirsa 在 Blackstone 出售部分股权后下跌。nL4N40K0YW ** Rivian Automotive Inc RIVN.O:BUZZ - 因DA Davidson在近期下滑后上调股票评级而上涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nL4T40K16B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVNL","IMUX","DIS","CVX","NUVB","XOMO","NEM","COP","SNDK","OCGN","RILY","NCEL","NWMX","OXY","CBRE","MU","RH","CAG","HAS","ZYME","ALKS","WDC","STX","XOM","NCNO","CYCN","FCX","SVC","SNXX","CALM","MUU","BYND","NNOX","NEMG","O","SCCO","AXSM","XOMZ","NKE","JANX","RIVN","PWR","DE","HON","SNAG","BX","TEX","MUD","MAXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624183805","title":"BUZZ-NewcelX 溢價融資以推動糖尿病項目，隨後股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2624183805","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624183805?lang=zh_tw&edition=fundamental","pubTime":"2026-04-01 19:36","pubTimestamp":1775043407,"startTime":"0","endTime":"0","summary":"BUZZ-NewcelX 溢价融资以推动糖尿病项目，随后股价上涨4月1日 - ** 生物技术公司NewcelX NCEL.O股价盘前上涨13.7%至2.41美元** 该公司表示，它通过私人配股筹集了资金，价格比上次收盘价高出30%。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nL4S40K0Z0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175524782","title":"Newcelx攜手Eledon製藥推進Ncel-101項目 開啓1型糖尿病治療新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1175524782","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175524782?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 19:03","pubTimestamp":1773054236,"startTime":"0","endTime":"0","summary":"生物技术公司Newcelx宣布与Eledon制药达成战略合作，双方将共同推进Ncel-101项目在1型糖尿病治疗领域的临床开发。这一合作标志着两家企业在细胞治疗领域的深度协同，有望为自身免疫性疾病患者带来突破性治疗方案。Ncel-101作为Newcelx的核心在研项目，其创新机制针对1型糖尿病的病理基础展开干预。通过整合Eledon制药在免疫调节领域的专有技术平台，该项目有望加速实现从实验室到临床的转化。业界观察人士指出，此次合作或将重塑糖尿病治疗的研发格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614773552","title":"Newcelx Ltd.盤中異動 早盤急速拉升5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614773552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614773552?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 22:57","pubTimestamp":1771945028,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日22时57分，Newcelx Ltd.股票出现异动，股价快速拉升5.48%。截至发稿，该股报2.79美元/股，成交量332股，换手率0.01%，振幅0.00%。Newcelx Ltd.股票所在的生物技术行业中，整体涨幅为0.37%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224225708a71a63e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224225708a71a63e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609517287","title":"Newcelx Ltd.盤中異動 臨近收盤股價大漲5.11%報2.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609517287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609517287?lang=zh_tw&edition=fundamental","pubTime":"2026-02-07 04:36","pubTimestamp":1770410218,"startTime":"0","endTime":"0","summary":"北京时间2026年02月07日04时36分，Newcelx Ltd.股票出现波动，股价大幅上涨5.11%。截至发稿，该股报2.78美元/股，成交量9751股，换手率0.21%，振幅4.55%。Newcelx Ltd.股票所在的生物技术行业中，整体涨幅为1.43%。Newcelx Ltd.公司简介：NewcelX Ltd 是一家生物技术公司，开发用于治疗神经退行性疾病和代谢性疾病的变革性细胞疗法和小分子疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207043659a485e10a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207043659a485e10a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}